Association of Nonalcoholic Fatty Liver Disease with Arterial Stiffness and its Metabolomic Profiling in Japanese Community-Dwellers
AIMS: Nonalcoholic fatty liver disease (NAFLD) is known to be associated with atherosclerosis. This study focused on upstream changes in the process by which NAFLD leads to atherosclerosis. The study aimed to confirm the association between NAFLD and the cardio-ankle vascular index (CAVI), an indicator of subclinical atherosclerosis, and explore metabolites involved in both by assessing 94 plasma polar metabolites.
METHODS: A total of 928 Japanese community-dwellers (306 men and 622 women) were included in this study. The association between NAFLD and CAVI was examined using a multivariable regression model adjusted for confounders. Metabolites commonly associated with NAFLD and CAVI were investigated using linear mixed-effects models in which batch numbers of metabolite measurements were used as a random-effects variable, and false discovery rate-adjusted p-values were calculated. To determine the extent to which these metabolites mediated the association between NAFLD and CAVI, mediation analysis was conducted.
RESULTS: NAFLD was positively associated with CAVI (coefficients [95% Confidence intervals (CI)]=0.23 [0.09-0.37]; p=0.001). A total of 10 metabolites were involved in NAFLD and CAVI, namely, branched-chain amino acids (BCAAs; valine, leucine, and isoleucine), aromatic amino acids (AAAs; tyrosine and tryptophan), alanine, proline, glutamic acid, glycerophosphorylcholine, and 4-methyl-2-oxopentanoate. Mediation analysis showed that BCAAs mediated more than 20% of the total effect in the association between NAFLD and CAVI.
CONCLUSIONS: NAFLD was associated with a marker of atherosclerosis, and several metabolites related to insulin resistance, including BCAAs and AAAs, could be involved in the process by which NAFLD leads to atherosclerosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of atherosclerosis and thrombosis - (2024) vom: 02. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hirata, Aya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atherosclerosis |
|---|
| Anmerkungen: |
Date Revised 08.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.5551/jat.64616 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368192814 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368192814 | ||
| 003 | DE-627 | ||
| 005 | 20240209232114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5551/jat.64616 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1285.xml |
| 035 | |a (DE-627)NLM368192814 | ||
| 035 | |a (NLM)38311416 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hirata, Aya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of Nonalcoholic Fatty Liver Disease with Arterial Stiffness and its Metabolomic Profiling in Japanese Community-Dwellers |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a AIMS: Nonalcoholic fatty liver disease (NAFLD) is known to be associated with atherosclerosis. This study focused on upstream changes in the process by which NAFLD leads to atherosclerosis. The study aimed to confirm the association between NAFLD and the cardio-ankle vascular index (CAVI), an indicator of subclinical atherosclerosis, and explore metabolites involved in both by assessing 94 plasma polar metabolites | ||
| 520 | |a METHODS: A total of 928 Japanese community-dwellers (306 men and 622 women) were included in this study. The association between NAFLD and CAVI was examined using a multivariable regression model adjusted for confounders. Metabolites commonly associated with NAFLD and CAVI were investigated using linear mixed-effects models in which batch numbers of metabolite measurements were used as a random-effects variable, and false discovery rate-adjusted p-values were calculated. To determine the extent to which these metabolites mediated the association between NAFLD and CAVI, mediation analysis was conducted | ||
| 520 | |a RESULTS: NAFLD was positively associated with CAVI (coefficients [95% Confidence intervals (CI)]=0.23 [0.09-0.37]; p=0.001). A total of 10 metabolites were involved in NAFLD and CAVI, namely, branched-chain amino acids (BCAAs; valine, leucine, and isoleucine), aromatic amino acids (AAAs; tyrosine and tryptophan), alanine, proline, glutamic acid, glycerophosphorylcholine, and 4-methyl-2-oxopentanoate. Mediation analysis showed that BCAAs mediated more than 20% of the total effect in the association between NAFLD and CAVI | ||
| 520 | |a CONCLUSIONS: NAFLD was associated with a marker of atherosclerosis, and several metabolites related to insulin resistance, including BCAAs and AAAs, could be involved in the process by which NAFLD leads to atherosclerosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a Branched-chain amino acids | |
| 650 | 4 | |a Cardio-ankle vascular index | |
| 650 | 4 | |a Insulin resistance | |
| 650 | 4 | |a Metabolites | |
| 650 | 4 | |a Nonalcoholic fatty liver disease | |
| 700 | 1 | |a Harada, Sei |e verfasserin |4 aut | |
| 700 | 1 | |a Iida, Miho |e verfasserin |4 aut | |
| 700 | 1 | |a Kurihara, Ayako |e verfasserin |4 aut | |
| 700 | 1 | |a Fukai, Kota |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwabara, Kazuyo |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Suzuka |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Minako |e verfasserin |4 aut | |
| 700 | 1 | |a Sata, Mizuki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyagawa, Naoko |e verfasserin |4 aut | |
| 700 | 1 | |a Toki, Ryota |e verfasserin |4 aut | |
| 700 | 1 | |a Edagawa, Shun |e verfasserin |4 aut | |
| 700 | 1 | |a Sugiyama, Daisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Asako |e verfasserin |4 aut | |
| 700 | 1 | |a Hirayama, Akiyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Sugimoto, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Soga, Tomoyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tomita, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Okamura, Tomonori |e verfasserin |4 aut | |
| 700 | 1 | |a Takebayashi, Toru |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of atherosclerosis and thrombosis |d 1997 |g (2024) vom: 02. Feb. |w (DE-627)NLM091773172 |x 1880-3873 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5551/jat.64616 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 02 | ||